AstraZeneca PLC (AZN)
NASDAQ: AZN · Real-Time Price · USD
85.04
-0.34 (-0.40%)
At close: Oct 9, 2025, 4:00 PM EDT
86.50
+1.46 (1.72%)
After-hours: Oct 9, 2025, 7:56 PM EDT
AstraZeneca Revenue
AstraZeneca had revenue of $14.46B in the quarter ending June 30, 2025, with 11.74% growth. This brings the company's revenue in the last twelve months to $56.50B, up 15.00% year-over-year. In the year 2024, AstraZeneca had annual revenue of $54.07B with 18.03% growth.
Revenue (ttm)
$56.50B
Revenue Growth
+15.00%
P/S Ratio
4.72
Revenue / Employee
$608,192
Employees
92,900
Market Cap
266.87B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 54.07B | 8.26B | 18.03% |
Dec 31, 2023 | 45.81B | 1.46B | 3.29% |
Dec 31, 2022 | 44.35B | 6.93B | 18.53% |
Dec 31, 2021 | 37.42B | 10.80B | 40.58% |
Dec 31, 2020 | 26.62B | 2.23B | 9.16% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
Thermo Fisher Scientific | 43.21B |
AZN News
- 14 hours ago - AstraZeneca breaks ground at $4.5 billion Virginia plant as drugmakers court Trump - Reuters
- 14 hours ago - AstraZeneca plans to increase investment and scope of its Virginia manufacturing facility to $4.5 billion, creating 3,600 new jobs - Business Wire
- 20 hours ago - Turbine Launches Collaboration with AstraZeneca, Leveraging Turbine's Virtual Disease Models to Rationalize ADC Discovery - PRNewsWire
- 2 days ago - Baxdrostat met the primary endpoint in Bax24 Phase III trial in patients with resistant hypertension - Business Wire
- 3 days ago - AstraZeneca's Baxdrostat meets main goal in high blood pressure study - Reuters
- 3 days ago - My Top 5 Biotech Stocks Big Pharma Could Buy Next - Seeking Alpha
- 3 days ago - AstraZeneca signs up to $555 million deal with US-based Algen to develop gene therapies - Reuters
- 3 days ago - Algen Biotechnologies Announces Multi-Target Partnership to Advance AI-Powered Drug Discovery in Immunology with AstraZeneca - Business Wire